Fig. 4.
Antitumor response with variation in epitope frequency under local Interleukin 10 blockade, a) Effect of mutation on orthotopic pancreatic tumor growth via bioluminescence imaging (n = 4–10). Day 10 post tumor inoculation, KPCF1 is a KPC cell line with KRASG12D mutation, 3F11 is a KPC cell line with KRASG12D/D153S mutation. Animals received either phosphate buffered saline (denoted as PBS) or 50 μg of IL-10 trap plasmid DNA (denoted as IL-10 t) administered via lipid-protamine-DNA (LPD) nanoparticles intravenously on Day 7 and 9 post orthotopic tumor cell inoculation, b) Treatment regimen for panel a. pDNA stands for plasmid DNA and BLI stands for bioluminescence imaging, c) Animals were sacrificed on Day 10 post orthotopic tumor inoculation, tumors were harvested, and mRNA Gene expression were quantified by qPCR (n = 16–18), d) Animals were sacrificed on Day 10 post orthotopic tumor inoculation, tumors were harvested, and immune cells were characterized and quantified by flow cytometry (n = 3). Data show mean ± SEM. * p < .05, ** p < .01, *** p < .001, **** p < .0001.